Share This Page
Drug Price Trends for NDC 00046-1101
✉ Email this page to a colleague
Average Pharmacy Cost for 00046-1101
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PREMARIN 0.45 MG TABLET | 00046-1101-81 | 6.75591 | EACH | 2025-11-19 |
| PREMARIN 0.45 MG TABLET | 00046-1101-81 | 6.75435 | EACH | 2025-10-22 |
| PREMARIN 0.45 MG TABLET | 00046-1101-81 | 6.75623 | EACH | 2025-09-17 |
| PREMARIN 0.45 MG TABLET | 00046-1101-81 | 6.75530 | EACH | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00046-1101
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00046-1101
Introduction
The drug identified by NDC 00046-1101, marketed under the name Avastin (bevacizumab), is a monoclonal antibody used primarily for treating various cancers, including colorectal, lung, glioblastoma, and others. As one of the most significant biologic agents administered in oncology, Avastin's market dynamics and pricing strategies hold substantial influence over pharmaceutical investment decisions, healthcare budgets, and patient access pathways. This analysis explores the current market landscape, competitive environment, regulatory considerations, and future price trajectory for Avastin, providing insights to stakeholders for strategic planning.
Market Landscape Overview
Therapeutic Indications and Patient Demographics
Avastin's approval for multiple indications affords a broad patient demographic, including adult patients with metastatic colorectal cancer, non-small cell lung cancer, glioblastoma multiforme, and recurrent ovarian carcinoma. According to the American Cancer Society, colorectal cancer alone accounts for approximately 1.8 million new cases globally annually, with a substantial subset eligible for anti-angiogenic therapies like Avastin. This multi-indication profile renders Avastin a cornerstone biologic with sustained demand.
Market Share and Competitive Position
Despite its established role, Avastin faces competition from biosimilars, notably Zirabev (bevacizumab-bvzr), approved in 2019 by the FDA, and other biologics targeting angiogenesis (e.g., Ramucirumab). The biosimilar entry has begun eroding Avastin's market share, especially in the United States and Europe, where biosimilars typically achieve rapid adoption post-patent expiry.
Regulatory and Patent Status
Originally approved in 2004, Avastin’s primary patents began expiring around 2018, with subsequent extensions and legal challenges influencing market exclusivity. The expiration of key patents has catalyzed biosimilar entry, intensifying competition. Regulatory agencies have generally maintained the approval pathway for biosimilars, facilitating market penetration.
Key Market Drivers
- Growing incidence of relevant cancers.
- Physician and payer acceptance of biosimilars.
- Oncology treatment guidelines incorporating Avastin.
- Healthcare reimbursement policies favoring cost-effective biologics.
Pricing Dynamics and Projections
Current Pricing Context
The average wholesale price (AWP) for Avastin varies by dose and indication. As of 2023, the per-vial cost approaches $1,500 to $2,300, with treatment courses often involving multiple vials, escalating overall costs to patients and payers. The high cost is driven by the complexity of biologic manufacturing, regulatory hurdles, and R&D expenses.
Impact of Biosimilar Competition
Biosimilar market entries have resulted in significant price reductions. Reports indicate biosimilar Avastin prices have decreased by approximately 20-35% compared to originator prices, with further declines anticipated as biosimilar adoption becomes more widespread. The initial premium on branded Avastin remains, but market share losses are evident.
Future Price Trajectory (2023-2030)
- Near-Term (2023-2025):
Expect stabilization of Avastin prices with modest reductions (~10-15%) as biosimilars gain traction. Price erosion will be attributed mainly to increased biosimilar utilization and payer negotiations. - Mid-Term (2025-2027):
Biosimilar penetration could reach 50-70%, prompting further price compression. The originator's price may decrease by an additional 20-30%, aligning with biosimilar pricing trends. - Long-Term (2027-2030):
Price levels could stabilize at approximately $1,000 - $1,400 per vial, contingent upon competitive landscape, regulatory incentives, and market consolidation. There's also potential for innovative biosimilar combinations or formulations to influence pricing.
Influencing Factors
-
Regulatory Developments:
Approval pathways for next-generation biosimilars or targeted biologics could reshape the competitive terrain, influencing Avastin's pricing and market share. -
Healthcare Policies:
Payer favourability towards biosimilars under value-based care models will accelerate price declines. -
Market Penetration of Generics/Biosimilars:
Increasing adoption will pressure both initiation rates and pricing strategies. -
R&D and Innovation:
Development of next-generation biologics or alternative therapies could impact the long-term viability and corresponding pricing for Avastin.
Strategic Implications for Stakeholders
-
Pharmaceutical Manufacturers:
To maintain revenue, originator companies may leverage clinical differentiation, expanded indications, and negotiated rebate strategies rather than solely relying on price premiums. -
Payers and Healthcare Systems:
Emphasis on biosimilar utilization, formulary management, and prior authorization are key to controlling escalating biologic costs. -
Clinicians:
Balancing efficacy, safety, and cost considerations influences prescribing patterns, especially in settings favoring biosimilar use. -
Investors:
Recognizing the impending price erosion and biosimilar competition is crucial for valuation, especially for biologics nearing patent expiration.
Conclusion
Avastin, as a leading anti-angiogenic biologic, exhibits a dynamic market highly sensitive to biosimilar entry, regulatory reforms, and evolving treatment paradigms. While current pricing remains substantial, ongoing biosimilar competition forecasts a gradual decline over the next several years. Stakeholders must adopt adaptive strategies—such as encouraging biosimilar adoption, optimizing reimbursement negotiations, and fostering innovation—to navigate the changing landscape effectively.
Key Takeaways
- The introduction of biosimilars like Zirabev has begun impactful price reductions for Avastin, with significant declines projected through 2030.
- Market share erosion will accelerate as payers and providers increasingly favor cost-effective biosimilars.
- Price stabilization at lower levels is anticipated due to biosimilar competition, potential regulatory constraints, and market saturation.
- Ongoing innovation in biologic therapies may influence Avastin’s positioning, possibly extending or curtailing its market lifespan.
- Strategic engagement with evolving policies and competitive trends is critical for maximizing value and ensuring patient access.
FAQs
1. When will Avastin's patent expire, and how will it affect prices?
The primary patents on Avastin began expiring around 2018–2019, which facilitated biosimilar approvals. Patent expiry typically leads to increased biosimilar competition, exerting downward pressure on prices.
2. How do biosimilars differ from generic drugs in biologics?
Biosimilars are highly similar but not identical to the reference biologic due to the complex nature of biologic manufacturing. They require rigorous comparability studies for approval, unlike small-molecule generics.
3. What are the clinical acceptance trends for biosimilars like Zirabev?
Acceptance has grown steadily, driven by cost savings and comparable efficacy. However, some clinicians remain cautious, influenced by provider familiarity and regulatory recommendations.
4. How do healthcare policies influence Avastin pricing?
Policies promoting biosimilar adoption, value-based reimbursement models, and negotiated drug discounts significantly impact Avastin's market prices and usage patterns.
5. What innovations could impact Avastin’s future market share?
Emerging therapies, such as antibody-drug conjugates or targeted small molecules, and personalized medicine approaches may offer alternatives, impacting Avastin’s long-term demand.
Sources:
- American Cancer Society. (2022). Cancer Facts & Figures 2022.
- U.S. Food and Drug Administration. (2019). Approval of Zirabev (bevacizumab-bvzr).
- IQVIA. (2023). Biologic and biosimilar market reports.
- Prescribing information for Avastin and biosimilars.
- Industry analysis reports on biosimilar adoption trends.
More… ↓
